Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy.

被引：1
|
作者：
Gupta, Shilpa
Agarwal, Neeraj
Konety, Badrinath R.
Weight, Christopher J.
Thyagarajan, Bharat
Murugan, Paari J.
Koopmeiners, Joseph S.
Sonpavde, Guru
机构：
[1] Univ Minnesota Mason Canc Ctr, Minneapolis, MN USA
[2] Huntsman Canc Hosp, Salt Lake City, UT USA
[3] Univ Minnesota, Minneapolis, MN USA
[4] Dana Farber Canc Inst, Boston, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.TPS528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS528
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer: A propensity score analysis
    Koie, Takuya
    Okamoto, Teppei
    Suzuki, Yuichiro
    Tobisawa, Yuki
    Yoneyama, Tohru
    Mori, Kazuyuki
    Yamamoto, Hayato
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Kamimura, Noritaka
    Ohyama, Chikara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [42] NEOADJUVANT GEMCITABINE PLUS CARBOPLATIN FOLLOWED BY IMMEDIATE RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: A PROPENSITY SCORE ANALYSIS
    Koie, Takuya
    Okamoto, Akiko
    Yamamoto, Hayato
    Tobisawa, Yuki
    Yoneyama, Tohru
    Mori, Kazuyuki
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kamimura, Noritaka
    Ohyama, Chikara
    [J]. JOURNAL OF UROLOGY, 2012, 187 (04): : E217 - E218
  • [43] Neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer: A propensity score analysis
    Koie, T.
    Okamoto, T.
    Suzuki, Y.
    Tobisawa, Y.
    Yoneyama, T.
    Mori, K.
    Yamamoto, H.
    Hatakeyama, S.
    Kudoh, S.
    Yoneyama, T.
    Kamimura, N.
    Ohyama, C.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E867 - U826
  • [44] Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy
    Gupta, Shilpa
    Sonpavde, Guru
    Weight, Christopher J.
    McGregor, Bradley Alexander
    Gupta, Sumati
    Maughan, Benjamin Louis
    Wei, Xiao X.
    Gibb, Ewan
    Thyagarajan, Bharat
    Einstein, David Johnson
    Dechet, Christopher B.
    Lowrance, William Thomas
    Murugan, Paari J.
    Kilbridge, Kerry L.
    Agarwal, Neeraj
    Davicioni, Elai
    Eckstein, Markus
    Mossanen, Matthew
    Preston, Mark A.
    Konety, Badrinath R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
    Cognetti, F.
    Ruggeri, E. M.
    Felici, A.
    Gallucci, M.
    Muto, G.
    Pollera, C. F.
    Massidda, B.
    Rubagotti, A.
    Giannarelli, D.
    Boccardo, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (03) : 695 - 700
  • [46] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Murasawa, Hiromi
    Koie, Takuya
    Ohyama, Chikara
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Iwabuchi, Ikuya
    Ogasawara, Masaru
    Kawaguchi, Toshiaki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (01) : 159 - 165
  • [47] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Hiromi Murasawa
    Takuya Koie
    Chikara Ohyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Ikuya Iwabuchi
    Masaru Ogasawara
    Toshiaki Kawaguchi
    [J]. International Journal of Clinical Oncology, 2017, 22 : 159 - 165
  • [48] Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
    Xing, N.
    Han, S.
    Jiang, J.
    Xu, W.
    Shi, B.
    Ping, H.
    Ji, Z.
    Ma, Q.
    Wang, H.
    Chen, S.
    Wang, W.
    Fan, X.
    Zhou, Q.
    Zhang, W.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S714 - S714
  • [49] Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study
    Okabe, Ko
    Shindo, Tetsuya
    Maehana, Takeshi
    Nishiyama, Naotaka
    Hashimoto, Kohei
    Itoh, Naoki
    Takahashi, Atsushi
    Taguchi, Keisuke
    Tachiki, Hitoshi
    Tanaka, Toshiaki
    Masumori, Naoya
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (10) : 934 - 941
  • [50] CISPLATIN AND GEMCITABINE NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: A SINGLE INSTITUTE EXPERIENCE
    Verri, Elena
    Mascia, Roberta
    Rocca, Maria Cossu
    Aurilio, Gaetano
    Cullura, Daniela
    Musi, Gennaro
    Cozzi, Gabriele
    Di Trapani, Ettore
    Russo, Andrea
    De Cobelli, Ottavio
    Nole, Franco
    [J]. ANTICANCER RESEARCH, 2018, 38 (04) : 2515 - 2518
12345